Page last updated: 2024-11-04

sevoflurane and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

sevoflurane has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies

Sevoflurane: A non-explosive inhalation anesthetic used in the induction and maintenance of general anesthesia. It does not cause respiratory irritation and may also prevent PLATELET AGGREGATION.
sevoflurane : An ether compound having fluoromethyl and 1,1,1,3,3,3-hexafluoroisopropyl as the two alkyl groups.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ruan, X1
Jiang, W1
Cheng, P1
Huang, L1
Li, X1
He, Y1
Mai, M1
Tan, Z1

Other Studies

1 other study available for sevoflurane and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

ArticleYear
Volatile anesthetics sevoflurane targets leukemia stem/progenitor cells via Wnt/β-catenin inhibition.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 107

    Topics: Anesthetics, Inhalation; Cell Differentiation; Cell Proliferation; Cell Self Renewal; Cell Survival;

2018